You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient disposition (safety population)

From: Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

Disposition, n (%) Diabetes n = 245 No diabetes n = 1802
Patients completing the studies 230 (93.9) 1726 (95.8)
Most common reasons for premature withdrawal from the study
 AEs 5 (2.0) 16 (0.9)
 Patient’s decision 6 (2.4) 29 (1.4)
Patients completing study drug 200 (81.6) 1528 (84.8)
Most common reasons for discontinuing study drug
 AEs 8 (3.3) 32 (1.8)
 Patient’s decision 7 (2.8) 36 (2.0)
 Lack of efficacy 5 (2.0) 11 (0.6)
  1. AE adverse event